Cellares Strengthens Leadership Team with Key Commercial and Advisory Appointments to Drive Cell Therapy Manufacturing Expansion
核心洞察
Cellares (搜索) appointed Ali Soleymannezhad as Chief Commercial Officer to lead global expansion and prepare for IPO, bringing two decades of platform commercialization experience from MaxCyte (搜索) and Tosoh Bioscience (搜索).
The company added Christopher McDonald, former Kite (搜索) Global Head of Technical Operations, to its Advisory Board to support global IDMO Smart Factory expansion with his extensive cell therapy manufacturing expertise.
These appointments come as Cellares (搜索) has secured five global manufacturing agreements with partners including Bristol Myers Squibb (搜索) and Kite (搜索), while receiving FDA's first Advanced Manufacturing Technology designation for a cell therapy platform.
Cellares (搜索), the world's first Integrated Development and Manufacturing Organization (IDMO), has made two strategic leadership appointments to accelerate its global expansion and prepare for a future IPO. The company appointed Ali Soleymannezhad as Chief Commercial Officer and Christopher McDonald to its Advisory Board, bringing decades of combined experience in cell therapy manufacturing and commercialization.
Commercial Leadership to Drive Global Expansion
Soleymannezhad joins Cellares (搜索) from MaxCyte (搜索) (NASDAQ: MXCT), where he served as Chief Commercial Officer, leading commercial strategy across sales, business development, marketing, and field applications. His appointment comes as Cellares prepares to support multiple clinical trials in 2026 and follows five global manufacturing agreements with partners including Bristol Myers Squibb (搜索), Kite (搜索), and leading academic institutions.
"Throughout my career, I've worked to bring breakthrough technologies to patients, but Cellares (搜索) is different," said Soleymannezhad. "Too many patients miss out on life-changing cell therapies because global manufacturing capacity simply can't keep pace. With Cellares' first-of-its-kind Cell Shuttle and global IDMO infrastructure, we finally have the ability to meet total patient demand."
At MaxCyte (搜索), Soleymannezhad expanded adoption across the United States, Europe, and Asia while securing enterprise agreements with leading biopharmaceutical companies. Previously, at Tosoh Bioscience (搜索), he directed global strategy and P&L, securing multi-year supply agreements that embedded the company's technologies into critical bioprocessing workflows.
Advisory Board Strengthened with Manufacturing Expertise
McDonald's appointment to the Advisory Board brings 35 years of operations experience, including his most recent role as Senior Vice President and Global Head of Technical Operations at Kite (搜索), a Gilead Company. At Kite, he oversaw Global Manufacturing, Global Quality, Process Development, and Global Supply Chain across six worldwide sites and more than 3,000 employees, supporting viral vector, clinical, and commercial cell therapy operations.
"Chris has scaled one of the industry's largest commercial cell therapy operations," said Fabian Gerlinghaus, co-founder and CEO of Cellares (搜索). "That experience is directly relevant as Cellares expands operations across the United States, Europe, and Japan and continues building an integrated manufacturing and quality control infrastructure that biopharma partners can trust at global scale."
McDonald previously held leadership roles at Amgen, Novartis, and AstraZeneca, and currently serves on the Board of Directors of Nucleus RadioPharma (搜索). He has also served on the board of Fosun Kite (搜索) in Shanghai.
Addressing Manufacturing Capacity Barriers
The appointments address critical challenges in cell therapy manufacturing, where capacity and cost-efficiency remain primary barriers preventing patient access to curative therapies. Most approved cell therapies today are personalized cancer (搜索) treatments produced one patient dose at a time, with sponsors relying on manual workflows in region-specific cleanrooms.
Cellares (搜索) offers a unified alternative through its IDMO Smart Factory network. The company's Cell Shuttle is the first end-to-end cell therapy manufacturing platform to receive the FDA's Advanced Manufacturing Technology (AMT) designation, providing expedited review and regulatory support for developers leveraging Cellares' services.
Technology Platform and Global Expansion
Cellares (搜索)' IDMO platform combines the proprietary Cell Shuttle (end-to-end automated cell therapy manufacturing) and Cell Q (high-throughput automated quality control) with a rapidly expanding global network of IDMO Smart Factories. This model delivers greater scalability at significantly lower cost than conventional CDMOs, enabling each Smart Factory to produce 10 times as many cell therapy batches as conventional facilities with the same size and headcount.
The company has automated more than half a dozen manual processes on the Cell Shuttle with a 100% automation success rate. This performance underpins the Biotech Incentive Program, through which Cellares (搜索) funds and executes process automation while assuming upfront technical risk.
Cellares (搜索) is headquartered in South San Francisco, California, with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company is building additional facilities in Europe and Japan and has raised over $355 million in financing from world-class investors.